Featured Clinical Trials - Lymphoma

The clinical research mission of the Lymphoma Program at Dana-Farber Brigham Cancer Center is to make the treatment of lymphoid malignancies more effective and targeted, while reducing toxicities. The program makes promising new therapies available to patients with a variety of lymphoid malignancies at every stage of disease, in a carefully monitored setting, through clinical trials.

The program’s research currently focuses on several areas, including:

Targeting tumors with drugs directed against specific molecular targets in lymphoid malignancies, or with antibodies reactive against tumor cell surface proteins, alone or linked to radionucleotides.
Targeting the tumor's "microenvironment" using inhibitors of angiogenesis (new blood vessel development) and stimulators of the immune response.

Our team is also leading several clinical trials of CAR T-cell therapy for lymphoma.

Many members of the clinical research team also have active programs of laboratory-based investigation in lymphoid malignancies. Researchers work closely with other scientists within Harvard Medical School-affiliated institutions.

To make a referral to one of the below clinical trials, please call: 617-632-6246

Disease

Trial Description

Principal Investigator

High-risk large B-cell lymphoma

22-467/NCT05605899: An adaptive phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of axicabtagene ciloleucel versus standard of care therapy as first-line therapy in subjects with high-risk large B-cell lymphoma

Caron A. Jacobson, MD, MMSc

Follicular lymphoma

Marginal zone lymphoma

22-632/NCT05783596: A phase 2 study of glofitamab and obinutuzumab for first-line treatment of follicular lymphoma and marginal zone lymphoma

Reid W. Merryman, MD

Follicular lymphoma

22-702/NCT05783609: A phase 2 study of epcoritamab and rituximab for first-line treatment of follicular lymphoma

Reid W. Merryman, MD

Mantle cell lymphoma

Newly diagnosed

21-040/NCT04855695: A phase 1/2 study of acalabrutinib, venetoclax, and obinutuzumab in patients with Relapsed/refractory and previously untreated mantle cell lymphoma

Austin Kim, MD

CLL, SLL

Newly Diagnosed

24-017/NCT06333262: A phase 2 study of fixed duration therapy with pirtobrutinib and obinutuzumab in previously untreated chronic lymphocytic leukemia (POP)

Inhye Ahn, MD

CLL, SLL

Relapsed/refractory

21-279/NCT05168930: A phase 2 trial of zanubrutinib and venetoclax in previously treated CLL/SLL patients

Inhye Ahn, MD

Richter’s transformation

23-429/NCT06043674: A phase 2 study of glofitamab as monotherapy or in combination with polatuzumab vedotin or atezolizumab in Richter’s transformation

Matthew Davids, MD, MMSc